CDC vaccine advisers recommend Merck’s RSV therapy for babies
A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.
A committee that advises the Centers for Disease Control and Prevention on vaccines voted Thursday to recommend the use of a new preventative therapy for RSV in babies, Merck’s Enflonsia.
The monoclonal antibody, given to babies under 8 months of age entering their first RSV season, is the second product of this kind to enter the market, joining Sanofi and AstraZeneca’s Beyfortus in the RSV toolkit.
